<DOC>
	<DOCNO>NCT00756873</DOCNO>
	<brief_summary>The aim study test analgesic efficacy etoricoxib ( 90 mg 120 mg qd . perioperatively ) post-operative pain relief . The primary endpoint follow : - preoperative etoricoxib reduce post-operative opioid utilization patient undergo elective tonsillectomy general anaesthesia ( i.e . post-operative opioid-sparing effect etoricoxib human ) . The secondary endpoint follow : - etoricoxib medication impact PONV activity daily - etoricoxib medication influence blood loss surgery incidence postoperative bleed - etoricoxib medication influence operation time . In addition , adverse effect etoricoxib document .</brief_summary>
	<brief_title>Etoricoxib Ear Nose Throat Surgery</brief_title>
	<detailed_description>On day surgery ( day 0 ) patient randomly assign one three group use seal envelope method . The etoricoxib 90 mg group receive etoricoxib ( Arcoxia® , Merck Sharp &amp; Dohme GmbH , Haar , Germany ) 90 mg orally , etoricoxib 120 mg group receive etoricoxib 120 mg orally control group receive placebo tablet orally 1 h surgery ( day 0 ) . All patient receive standard general anesthesia intravenous propofol ( 2-3 mg/kg ) , fentanyl ( 2 µg/kg ) mivacurium ( 0.2 mg/kg ) induction . Patients ventilate via tracheal tube , anesthesia maintain sevoflurane ( 0.8 - 1.5 % end-tidal concentration ) . If mean arterial blood pressure heart rate increase 25 % pre-operative baseline value despite end-tidal concentration 1.5 % sevoflurane , intravenous bolus fentanyl 0.05 mg administer . Monitoring include electrocardiogram ( ECG ) , non-invasive arterial blood pressure , pulse oximetry , end-tidal CO2 end-tidal sevoflurane . On day 1 3 patient receive etoricoxib ( 90 mg 120 mg qd . ) placebo . After discharge day 3 , patient receive etoricoxib ( 90 mg 120 mg qd . ) placebo cessation pain activity ( swallow ) . According current label Arcoxia® 120 mg Germany , patient take etoricoxib 120 mg switch etoricoxib 90 mg day 8 . Rescue medication piritramid i.v . ( day 0 ) , oxycodone p.o . ( day 1-2 ) paracetamol p.o . ( day 3-14 ) . Day -7 -1 : Inclusion/exclusion criterion , medical history , concomitant medication , laboratory , serum pregnancy test , informed consent Day 0 : Study medication 1 h surgery , intra-operative blood loss , pain score , opioid utilization , PONV score anti-emetic medication Day 1 : pain score , opioid utilization , PONV score , anti-emetic medication , bleed Day 2 : pain score , opioid utilization , PONV score , anti-emetic medication , bleed Day 3 : pain score , opioid utilization , PONV score , anti-emetic medication , bleed Day 7 : pain score , paracetamol utilization , bleed Day 14 : first day pain , last study medication , paracetamol utilization , bleed</detailed_description>
	<mesh_term>Etoricoxib</mesh_term>
	<criteria>male female patient 18 year age female patient pregnant/nonlactating indication elective tonsillectomy write informed consent . etoricoxib , analgesic antiemetic medication within 10 halflives evidence active peptic ulceration history gastrointestinal bleeding evidence hepatic , renal hematopoietic disorder heart failure ( NYHA IIIV ) uncontrolled arterial hypertension clinical evidence arterial occlusive disease coronary heart disease cerebrovascular disease inflammatory bowel disease hypersensitivity analgetics , antipyretic , NSAIDs antiemetic evidence noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Elective tonsillectomy</keyword>
</DOC>